化学信息：
| 化学名 | N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide |
|
| 简称 | ABT-333 | |
| 别名 |
Dasabuvir, ABT333, ABT 333 |
|
| 中文名 | N/A | |
| 化学式 | C26H27N3O5S | |
| 分子量 | 493.57 | |
| CAS号 | 1132935-63-7 | |
| 纯度 | 98% | |
| 溶剂/溶解度 |
Water<1mg/ml; DMSO6mg/ml; Ethanol<1mg/ml |
|
| 溶液配制 | 5mg加入1.01ml DMSO，或者每4.94mg加入1ml DMSO，配制成10mM溶液。SC3256-10mM用DMSO配制。 |
生物信息：
| 产品描述 | ABT-333 is an NS5B non-nucleoside polymerase inhibitor. | ||||
| 信号通路 | Anti-infection | ||||
| 靶点 | HCV NS5B | － | － | － | － |
| IC50 | － | － | － | － | － |
| 体外研究 | N/A | ||||
| 体内研究 | All patients received ABT-333 (400mg twice daily) and ribavirin (1000 to 1200mg per day) and one of two daily doses of ABT-450/r. Groups 1 and 2 included previously untreated patients; group 1 received 250mg of ABT-450 and 100mg of ritonavir, and group 2 received 150mg and 100mg, respectively. Group 3, which included patients who had had a null or partial response to previous therapy with peginterferon and ribavirin, received daily doses of 150mg of ABT-450 and 100mg of ritonavir. An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. | ||||
| 临床实验 | N/A | ||||
| 特征 | N/A | ||||
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
| 酶活性检测实验 | |
| 方法 | N/A |
| 细胞实验 | |
| 细胞系 | N/A |
| 浓度 | N/A |
| 处理时间 | N/A |
| 方法 | N/A |
| 动物实验 | |
| 动物模型 | N/A |
| 配制 | N/A |
| 剂量 | N/A |
| 给药方式 | N/A |
| 产品编号 | 产品名称 | 包装 |
| SC3256-10mM | ABT-333 (HCV抑制剂) | 10mM×0.2ml |
| SC3256-5mg | ABT-333 (HCV抑制剂) | 5mg |
| SC3256-25mg | ABT-333 (HCV抑制剂) | 25mg |
| — | 说明书 | 1份 |
保存条件：
-20℃保存，至少一年有效。5mg和25mg包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
